

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Old et al.)
)
Serial No.: Not yet assigned)
)
Filed: Herewith)
)
For: 8-AZAPROSTAGLANDIN)
CARBONATE AND)
THIOCARBONATE ANALOGS)
AS THERAPEUTIC AGENTS)
)

Group Art Unit: Not yet assigned

Examiner: Not yet assigned

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as Express Mail (Label No. EV193717995US) in an envelope addressed to: Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on:

Date of Deposit: 1/26/04Person making Deposit: BONNIE FERGUSONSignature: Bonnie FergusonDate of Signature: 1/26/04INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Alexandria, VA 22313-1450

Dear Sir:

Applicant herewith submits forms PTO 1449 for consideration by the Examiner, consistent with the provisions of 37 CFR § 1.97 and 1.98. By submitting this Information Disclosure Statement, Applicant makes no admission that any item listed thereupon is material to the patentability of the invention claimed in the above-entitled patent application. Further, Applicant makes no assertion hereby that a search was conducted, or if conducted, that any search was thorough.

Applicant respectfully requests that the Examiner indicate consideration of the presently cited references by returning the enclosed Form 1449 bearing the Examiner's initials and the date considered.

Date: 1/23/04

Respectfully submitted,

RJ Baran

Robert J. Baran
Reg. No. 25,806
ALLERGAN, INC. -T2-7H
2525 Dupont Drive
Irvine, CA 92612
Tel: 714-246-4669
Fax: 714-246-4249

An Information Disclosure Statement consisting of two pages was filed on June 2, 2003, in parent application serial number 10/453,818. Copies of the references provided during prosecution of the parent application which were cited therein are not included with this IDS.

LIST OF PRIOR ART CITED BY APPLICANT

ATTY. DOCKET: 17581DIV(AP)	SERIAL NO.: N/A
APPLICANT: Old et al	8-AZAPROSTAGLANDIN CARBONATE AND THIOCARBONATE ANALOGS AS AGENTS THERAPEUTIC AGENTS
FILING DATE: Submitted herewith	GROUP: n/a

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
	AA	5,446,041	8/29/1995	Chan et al			
	AB	4,994,274	2/19/1991	Chan et al			
	AC	5,028,624	7/2/1991	Chan et al			
	AD	5,034,413	7/23/1991	Chan et al			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
	AE	WO01/46140 A1	6/28/2001	PCT			
	AF	WO 03/007941 A1	1/30/2003	PCT			
	AG	WO 02/24647 A1	3/28/2002	PCT			
	AH	WO 02/042268A2	5/30/2002	PCT			
	AI	EP 1 121 939 A2	8/8/2001	EP			
	AJ	2001-233792	8/28/2001	JP			
	AK	03/009872 A1	6/2/2003	PCT			

OTHER PRIOR ART

(Including Author, Title, Date, Pertinent Pages, etc.)

	AL		Bito, L.Z., <u>Biological Protection with Prostaglandins</u> , Cohen, M.M., ed., Boca Raton, Fla, CRC Press Inc., 1985, pp. 231-252
	AM		Bito, L.Z., <u>Applied Pharmacology in the Medical Treatment of Glaucomas</u> , Drance, S.M. and Neufeld, A.H. eds, New York, Grune & Stratton, 1984, pp. 477-505
	AN		Nilsson et al, Invest. <u>Ophthalmol. Vis. Sci.</u> (suppl), 284 (1987)
	AO		Bito, L.Z., <u>Arch. Ophthalmol.</u> 105, 1036 (1987)
	AP		Siebold et al, <u>Prodrug</u> 5 3 1989

EXAMINER _____ DATE CONSIDERED _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.